Brazil claims successful test of parasite vaccine
Brazilian researchers say they have successfully tested a vaccine against schistosomiasis, a disease caused by parasitic worms that afflicts more than 200 million people worldwide.
"This is an unprecedented breakthrough in medicine that involved 30 years of scientific work," Dr Tania Araujo-Jorge, of the Oswaldo Cruz Institute in Rio de Janeiro, said Tuesday. The institute receives public and private funding.
"We are confident that within three years Brazil will be able to distribute the first vaccine against parasites, and help combat schistosomiasis, a disease that strikes the poorest because it is spread by unsanitary conditions."
The vaccine against the parasite, which also afflicts cattle, was developed from the reconstruction of a protein found in a species of worm.
The institute said it had successfully tested the vaccine in humans, but that more testing would be required in areas where the parasite is most common, mainly in Africa and South America.
The freshwater parasite can penetrate people's skin, and children are at especially high risk because they swim and bathe in contaminated water.
Brazil has some 2.5 million cases of schistosomiasis, which initially causes an itchy rash, followed in subsequent weeks by fever, chills, coughing and muscle aches. After a few years, the disease can damage internal organs.
"While the mortality rate is low, schistosomiasis causes incapacity, which makes it a disease that is caused by poverty and one that perpetuates poverty," Araujo-Jorge said.
(c) 2012 AFP
-
Worm 'cell death' discovery could lead to new drugs for deadly parasite
Sep 28, 2011 |
not rated yet |
0
-
Genetic code cracked for a devastating blood parasite
Jan 18, 2012 |
not rated yet |
0
-
Crucial gene activator in slow-killing parasite identified
Jan 05, 2012 |
not rated yet |
0
-
Parasite infects poor women's reproductive organs
Oct 28, 2010 |
not rated yet |
0
-
Multiple malaria vaccine offers protection to people most at risk
Oct 26, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Feds fight morning-after pill age ruling in NY
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Medications
20 hours ago |
not rated yet |
0
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
First drug to improve heart failure mortality in over a decade
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Heart failure accelerates male 'menopause'
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Seniors more likely to crash when driving with pet, study finds
(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...
New immune system discovered
(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.
Death highest in heart failure patients admitted in January, on Friday, and overnight
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
Brain can be trained in compassion, study shows
Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.